当然，风险亦不容忽视。Infigratinib是泛FGFR1-4抑制剂，对FGFR1等的抑制可能引起高磷血症等副作用。3期试验中约有4%患者出现轻度、短暂的高磷血症。在儿科长期用药的背景下，其安全性仍需更严格的监测，监管的要求也会更严格。
From April it will become a contractual requirement to monitor this and achieve it in 90% of cases.，详情可参考safew官方版本下载
luajit-2.1.1748459687-2.fc42.x86_64，这一点在搜狗输入法2026中也有详细论述
How to find programs on CJ affiliates?